Cyrus Harmon
Chief Research Officer at Olema Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Olema Pharmaceuticals Inc., 3 years.
Olema Pharmaceuticals Inc.
Director · Chief Research Officer
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 30, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −934 | $15.55 | $14,524 |
| Jul 29, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −4,066 | $15.58 | $63,348 |
| Jul 11, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −5,000 | $12.26 | $61,300 |
| Jun 28, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −20,000 | $10.77 | $215,400 |
| Jun 4, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −5,000 | $12.33 | $61,650 |
| Jun 3, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −5,000 | $10.93 | $54,650 |
| May 31, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −15,000 | $9.41 | $141,150 |
| May 6, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −5,000 | $10.92 | $54,600 |
| Apr 30, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −15,000 | $9.51 | $142,650 |
| Mar 28, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −20,000 | $10.97 | $219,400 |
| Feb 29, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −24,900 | $12.41 | $309,009 |
| Feb 29, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −100 | $13.00 | $1,300 |
| Feb 1, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −5,000 | $15.56 | $77,800 |
| Jan 31, 2024 | Olema Pharmaceuticals Inc. | Open-market sale | −25,000 | $12.23 | $305,750 |
| Dec 29, 2023 | Olema Pharmaceuticals Inc. | Open-market sale | −22,500 | $13.30 | $299,250 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.